Minor histocompatibility antigens are highly immunogeneic polymorphic peptides playing crucial roles in the clinical outcome of HLA-identical allogeneic stem cell transplantation. Although the introduction of genome-wide association-based strategies significantly accelerated the identification
Introduction
For several hematological malignancies allogeneic stem cell transplantation (allo-SCT) from an HLAidentical donor, alone or followed by donor lymphocyte infusion (DLI) is a potentially curative immunotherapeutic option. (1) (2) (3) (4) Besides the rescue of the recipient's hematopoietic system, the infused graft can mediate a powerful graft-versus-tumor (GvT) reaction to induce long term remissions. Despite this curative potential, allo-SCT is currently not recommended as the first-line treatment for several hematological malignancies, because it frequently causes a detrimental graftversus-host-disease (GvHD). In an HLA-identical setting, both GvT and GvHD are predominantly driven by donor T cells, which are directed at allogeneic peptides presented on the HLA molecules of the recipient.(5-10) These highly immunogenic, non-HLA encoded allogeneic peptides are historically, perhaps mistakenly, designated as minor histocompatibility antigens (mHags). To date, after the identification of almost 50 autosomal mHags (Supplementary Table 1 ), it is evident that mHags are generated by intracellular degradation of polymorphic proteins. The genetic bases of these polymorphisms are either single nucleotide polymorphisms (SNPs), base pair insertions or deletions (indels) or copy number variations (CNVs). (11) In the mid-nineties, the discovery that a specific set of mHags is solely expressed on malignant and non-malignant hematopoietic cells, shifted the paradigm on mHags and suggested that hematopoietic-restricted mHags could be ideal targets for separating
GvT from GvHD.(1;12;13) Nonetheless, a thorough clinical evaluation of this appealing concept has not been realized yet, because the small number of genuinely hematopoietic system-specific mHags identified so far permits the inclusion of not even 20% of the transplant patients in the slowly-running clinical trials. Thus, a timely clinical evaluation of mHag-based immunotherapy is highly dependent on the development of more rapid and robust strategies for identification of mHags.
The classical strategy to identify mHags is via the characterization of the epitope recognized by mHag-specific T cell clones isolated from allo-SCT recipients. The first series of mHags were identified using demanding methods, such as peptide elution from HLA-molecules or screening of cDNA libraries derived from mHag-positive cells. (14) (15) (16) (17) (18) After the discovery that mHags are products of polymorphic genes, these techniques were replaced by genetic strategies that made use of the correlation of mHag phenotypes with large numbers of genetic variations, derived from databases such as the HapMap Project or self-assembled panels. (12;19-27) Although these genetic techniques proved to be successful and revealed the identity of >15 mHags, they all are still limited by the fact that the used databases do not include all existing genetic variations and variation types (i.e. indels and CNVs).
Recently, the so called 1000 Genomes Project created a nearly complete map of more than 40 million variations in 14 human populations by full-genome deep sequencing of 1092 individuals, including SNPs, indels and CNVs.(28) Set out to overcome the drawbacks of all previous methods, we now developed a new genetic approach using the databases of the 1000 Genomes Project. Similar to earlier approaches, this new method is based on the functional mHag phenotyping of individuals by testing their antigen-presenting cells for recognition by mHag-specific T cells. Subsequently these phenotypes are correlated to all the genotypic variations included in the 1000 Genomes Project.
We here demonstrate the power of this new strategy by the rapid and unambiguous identification of the HLA-DP4 restricted mHag UTDP4-1, which despite great efforts in the past 15 years, could not be identified with any of the previously developed strategies, including our earlier developed HapMapbased strategy.
Methods

Cells
The CD4
+ mHag-specific cytotoxic T cell (CTL) clone 3AB11 was generated as described previously. (29) In short, T cells were isolated from a multiple myeloma patient after allo-SCT.
Several T cell clones were generated of which 3AB11 displayed patient-specific cytotoxicity and was selected for additional experiments. T cells were cultured in RPMI 1640 supplemented with 10% human serum and standard antibiotics. 
EBV-transformed B cells (EBV-LCL
Flow cytometry
Cells labelled with fluorochrome-conjugated antibodies (BD and Beckman Coulter) were analyzed with a FACS Calibur flow cytometer (BD). Acquired data were analyzed with CellQuest software (BD).
Enzyme linked immunosorbent assay (ELISA)
The interferon gamma (IFNγ) content of cell-free supernatants was determined using a commercial ELISA kit (Sanquin, Pelipair) according to the manufacturer's instructions. For all samples at least duplicates were measured.
Phenotyping HapMap individuals
The mHag phenotypes of the individuals from HapMap trios (father-mother-child) were determined with IFNγ ELISA, using their EBV-LCLs as antigen presenting cells for CTL clone 3AB11. If necessary, the EBV-LCLs were first retrovirally transduced with HLA-DPB1*0401, as described elsewhere.(30) EBV-LCLs were considered mHag + if the mean absorbance value at 450 nm of triplicate tests was >0.300 (3-5 times the background absorbance value of EBV-LCLs or T cells).
They were considered mHag -if the mean absorbance value at 450 nm of triplicate tests was <0.100
(comparable to background levels). Results between 0.100 and 0.300 were repeated or ignored for analyses.
Genome-wide zygosity-genotype correlation analysis
The correlation of experimental data with HapMap SNP genotypes was performed and analyzed as previously described.(12;24;25) In short, after mHag phenotypes were determined mHag zygosities of these individuals were deduced using the inheritance pattern within the family trios. These zygosities were correlated to the ~4 million SNPs included in the HapMap database (release #24), using the software ssSNPer. (25) 
Genomes Project correlation analysis
The correlation between mHag phenotypes of individuals included in the 1000 Genomes Project and the >40 million variations of these individuals was analyzed using the free software environment R, 
Results
Implementation of the 1000 Genomes Project in mHag-specific GWAS.
For the new genetic approach, 1000 Genomes Project genotype files were downloaded and used as input for an R-script specifically developed to determine the assocation between the mHag phenotypes and the genotypes of every single genetic variation within the 1000 Genomes Project database. Since several of the 1092 individuals present in the 1000 Genomes Project were also included in the HapMap project, we first validated the new strategy by re-identification of the mHag UTA2-1, which we previously identified using the HapMap-based zygosity-phenotype analysis (data not shown). (24) Next we confirmed that the genetic variations encoding for all known mHags are included in the 1000
Genomes Project, implying that all of them could have been identified using this new method (Table   S1 ).
Most previously identified mHags have a clinically relevant frequency in different ethnic
populations.
The 1000 Genomes Project database contains genetic information of individuals from 14 ethnic populations from various continents. This comprehensive resource not only facilitates the identification of mHags, but it also enabled us to analyze various important characteristics of previously identified mHags. Most importantly, for each currently known mHag we determined its frequency in different ethnic populations, revealing that the phenotype frequencies of all mHags display significant variation from population to population. This, first of all, has an impact on the mHag identification strategy. For instance, if too-high or too-low phenotype frequencies are observed in the primary test population, it will be beneficial to extend the correlation analysis to other populations (as exemplified by group B in Figure 1 and Table S1 ).
Furthermore, this analysis revealed that the frequency of only eight mHags was between the 26-78% boundaries in all populations ( Figure 1 and Table S1 , group A). We have previously reported that this boundary defines the clinical applicability of a mHag, because for mHags with a frequency beyond these boundaries the odds for a mHag mismatch between donor and patient are very small.(12) Hence, there are only eight "universally important" therapeutic mHags identified so far. On the other hand however, we also found that there are only seven "universally non-relevant" mHags with a frequency beyond the 26-78% boundaries in all populations ( Figure 1 and Table S1 , group C). Thus, the majority of mHags identified until now are clinically relevant in at least one ethnic population.
Identification of the new HLA class II restricted mHag UTDP4-1 with the 1000 Genomes
Project-based approach
After establishing that this new strategy had sufficient power to identify all previously discovered mHags, we evaluated its value in identifying a new mHag. For this, we chose the HLA-DP*0401-restricted mHag recognized by the CD4 + T cell clone 3AB11, because we could not unravel its target peptide, despite our great efforts in the past 15 years. Notably, our earlier attempts including a cDNAscreening and pairwise genetic linkage studies failed (data not shown). Recently, using our genomewide zygosity-genotype correlation analysis based on family trios of the HapMap Project,(12) we mapped this mHag with a low confidence r 2 =0.68 to a genetic locus on chromosome 9 defined by rs12551834 ( Figure 2A ). Still we could not identify it, even after an extensive analysis of all missense SNPs in a large genetic region (0.5 Mbp) around rs12551834. For both genetic analyses together, we phenotyped 146 individuals in total but were not able to pinpoint the mHag encoding variation. Since 43 of these are included in the 1000 Genomes Project, we executed a new genetic analysis, this time correlating the mHag phenotypes with the comprehensive dataset of the 1000 Genomes Project.
Remarkably, and consistent with our previous findings, we found a very strong correlation, with significant p-values around 10 -7 , between the mHag phenotype and the locus on chromosome 9
( Figure 2A ). In contrast to our earlier analyses, however, the locus was now defined by nine genetic variations of which seven were 100% correlated with the phenotype data of the 43 individuals.
Retrospective analyses revealed that these variations were not included in the databases of the HapMap Project and are located just 9600 basepairs outside of the large region previously analyzed based on the HapMap Project correlation analysis. Interestingly, according to the current gene annotations of Ensembl, rs11539209 is the only of these seven polymorphisms encoding for a missense variation, suggesting that this SNP could be responsible for our long-sought mHag.
The newly identified mHag UTDP4-1 is encoded by ZDHHC12
SNP rs11539209 gives rise to an A-to-T nucleotide switch, leading to an amino acid substitution from asparagine (N) to isoleucine (I) in ZDHHC12 (zinc finger, DHHC-type containing 12) ( Figure 2B ).
By testing the recognition of a 29-mer peptide with the altered amino acid in the middle, covering all possible ≤15-meric T cell epitopes, we confirmed that this SNP indeed encoded the mHag targeted by clone 3AB11 (data not shown). Subsequently all 15-mer peptides containing the isoleucin at shifting positions were screened for recognition by 3AB11 and several peptides indeed stimulated IFNγ production ( Figure 2C ). We designated this new mHag UTDP4-1. The minimal amino acid sequence required for a positive response was RILAHFFCGW. Also, the allelic counterparts containing the asparagine amino acid were screened, but none of these peptides was recognized by clone 3AB11.
Discussion
In this study, we provide proof on the feasibility, accuracy and efficacy of a new strategy for the identification of mHags based on the comprehensive genomic variation data collected by the 1000
Genomes Project. Our study design and results are in concordance with the fundamental idea of the 1000 Genomes Project, which was initiated to provide a complete overview of all human sequence variations, towards understanding the relationship between genotype and phenotype.(28) Importantly, the successful and rapid identification of mHag UTDP4-1, illustrates that this new 1000 Genomes
Project-based strategy can overcome many drawbacks encountered so far in the identification of mHags.
Among the many mHag identification strategies developed so far, the non-genetic ones were the most cumbersome. In fact, these methods were originally developed for the identification of HLA class I Previously we reported that identification of mHags beyond 10-85% prevalence would not be useful, since such mHags will contribute too little to broad application of mHag-based therapies.(12) While this idea is still valid, the analysis of the diverse populations in the 1000 Genomes Project revealed that mHags with seemingly unfavourable frequencies in a certain population may still be broadly applicable in other ethnic populations. Ultimately, this improved knowledge on mHags may lead to superior identification strategies through the design of directed algorithms towards the computational prediction of true immunotherapeutic mHags. (11;32;33) In conclusion, the new approach integrating all variations of the 1000 Genomes Project currently represents the most appealing method for highly efficient mHag identification. This methodology will conceivably facilitate the identification of the broad set of mHags that are not only necessary for the optimal setup of mHag-based immunotherapy trials but also for a better understanding of mHag immunobiology. Table S1 ) the genotypes of all 1092 individuals were extracted from the 1000 Genomes Project datasets. Based on these data, the phenotype frequencies were calculated for each ethnic population separately. Depicted are these frequencies, color-sorted by continent and divided in three groups: A) the phenotype frequencies of all populations are in between 26-78% (dashed lines), B) the phenotype frequencies of several but not all populations are in between 26-78%, and C) none of the phenotype frequencies of the various populations are in between 26-78%. Table S1 provides the exact values for each currently known mHag in each population in the same order. 
